Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;97(45):e13160.
doi: 10.1097/MD.0000000000013160.

Tumor necrosis factor-alpha-308 gene promoter polymorphism associates with survival of cancer patients: A meta-analysis

Fengshuang Yi  1 , Xinyu Shi  2 , Xuebin Pei  2 , Xiuzhi Wu  2
Affiliations
Review

Tumor necrosis factor-alpha-308 gene promoter polymorphism associates with survival of cancer patients: A meta-analysis

Fengshuang Yi et al. Medicine (Baltimore). 2018 Nov.

Abstract

Background: Tumor necrosis factor-alpha (TNF-α) is involved in cancer pathogenesis, and TNF-α-308G>A, a single-nucleotide polymorphism, is associated with cancer prognosis; however, different studies have reported inconsistent results. This meta-analysis aimed to determine the correlation between TNF-α-308G>A polymorphism and the survival of cancer patients.

Methods: PubMed, Web of Science, Embase, Wanfang database, VIP database, and China National Knowledge Infrastructure database were used to obtain articles on association between TNF-α-308G>A polymorphism and cancer survival, published until April 2018. A meta-analysis was carried out using Stata 12.0 software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CI). Furthermore, publication bias was assessed, and sensitivity analysis was performed to validate the analysis.

Results: In total, 13 retrospective cohort studies including 2559 cancer patients were reviewed to estimate the association between TNF-α-308G>A polymorphism and overall survival (OS) of cancer patients. The pooled results suggested that within TNF-α-308G>A polymorphism, genotypes GA+AA/GG (HR = 1.39, 95% CI: 0.90-2.14, P < .001, I = 78.1%), GA/GG (HR = 1.06, 95% CI: 0.83-1.36, P = .072, I = 53.5%), and AA/AG+GG (HR = 3.28, 95% CI: 0.92-11.72, P = .001, I = 85.9%) were not associated with the OS of cancer patients. However, interestingly, the HR was greater for patients with the AA genotype than for those with the GG genotype, suggesting an association between TNF-α-308G>A polymorphism and OS among cancer patients (AA/GG, HR = 2.16, 95% CI: 1.36-3.43, P = .281, I = 21.5%).

Conclusion: TNF-α-308G>A polymorphism affects the OS of cancer patients and is a potential therapeutic target for cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Overall association between TNF-α-308G>A polymorphism and the overall survival of cancer patients (genotype GA+AA/GG). The hazard ratios (HRs) in the studies and the corresponding 95% confidence intervals (CIs) are plotted with horizontal lines. Pooled HR and the corresponding 95% CI values are denoted by the diamond symbol. TNF-α = tumor necrosis factor-alpha.
Figure 2
Figure 2
Overall association between TNF-α-308G>A polymorphism and the overall survival of cancer patients (genotype GA/GG). The hazard ratios (HRs) in the studies and the corresponding 95% confidence intervals (CIs) are plotted with horizontal lines. Pooled HR and the corresponding 95% CI values are denoted by the diamond symbol. TNF-α = tumor necrosis factor-alpha.
Figure 3
Figure 3
Overall association between TNF-α-308G>A polymorphism and the overall survival of cancer patients (genotype AA/GG). The hazard ratios (HRs) in the studies and the corresponding 95% confidence intervals (CIs) are plotted with horizontal lines. Pooled HR and the corresponding 95% CI values are denoted by the diamond symbol. TNF-α = tumor necrosis factor-alpha.
Figure 4
Figure 4
Overall association between TNF-α-308G>A polymorphism and the overall survival of cancer patients (genotype AA/GA+GG). The hazard ratios (HRs) in the studies and the corresponding 95% confidence intervals (CIs) are plotted with horizontal lines. Pooled HR and the corresponding 95% CI values are denoted by the diamond symbol. TNF-α = tumor necrosis factor-alpha.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630–2. - PubMed
    1. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 1985;13:6361–73. - PMC - PubMed
    1. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45–53. - PubMed
    1. Tang P, Hung MC, Klostergaard J. Human pro-tumor necrosis factor is a homotrimer. Biochemistry 1996;35:8216–25. - PubMed
    1. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 2016;12:49–62. - PMC - PubMed

Substances